RudyBalasko / iStockphoto.com
Ahead of the Unitary Patent & Unified Patent Court 2017 conference in Munich on July 5, Jörg Thomaier, CEO of Bayer Intellectual Property Gmbh, discusses how the pharmaceutical company will approach opting its patents into or out of the new system.
As the CEO and head of the IP department of Bayer, what is your approach to the new unitary patent system?
We have always been extremely supportive of the system. We are one of the driving forces behind it from a German industry perspective, I would say. We want to keep the UK in the system, if possible; we are very positive.
How much use of the unitary patent is Bayer likely to make?
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at email@example.com
Jörg Thomaier, CEO of Bayer Intellectual Property, Unitary Patent & Unified Patent Court 2017 , pharmaceutical companies, Europe